| Not Yet Recruiting | Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test NCT07430410 | CorDx, Inc. | N/A |
| Recruiting | Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS NCT07189936 | Vanderbilt University Medical Center | Phase 2 |
| Active Not Recruiting | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age NCT07300839 | BioNTech SE | Phase 3 |
| Not Yet Recruiting | Efficacy and Safety of NVX-CoV2705 NCT07086222 | Novavax | Phase 4 |
| Active Not Recruiting | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of NCT07222384 | BioNTech SE | Phase 3 |
| Recruiting | A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to I NCT06810934 | Kara Chew | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Immunogenicity of NVX-CoV2705 NCT07079670 | Sanofi | Phase 3 |
| Recruiting | Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients NCT07197164 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 2 |
| Not Yet Recruiting | Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19) NCT05633446 | Gylden Pharma Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participa NCT07069309 | BioNTech SE | Phase 3 |
| Active Not Recruiting | Pancoronavirus Vaccine Study in Healthy Adults NCT06950177 | Duke University | Phase 1 |
| Not Yet Recruiting | Evaluation of the Diagnostic Performance of the TestNPass DM-DIV for SARS-CoV-2 Using a Nasopharyngeal Sample NCT06917261 | University Hospital, Grenoble | N/A |
| Recruiting | Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2 NCT06099795 | Centre Hospitalier Universitaire de Nīmes | N/A |
| Not Yet Recruiting | Collection of Additional Biological Samples From Potentially COVID-19 Patients for Monitoring of Biological Pa NCT06144333 | CerbaXpert | N/A |
| Completed | Dose, Safety and Pathogenicity of SARS-CoV-2 (COVID-19) Omicron Virus (BA.5) NCT06492564 | Hvivo | EARLY_Phase 1 |
| Recruiting | Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopul NCT06631287 | Wes Ely | Phase 3 |
| Recruiting | CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools NCT06640387 | The Hospital for Sick Children | — |
| Completed | An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID. NCT05911906 | University of Derby | Phase 4 |
| Active Not Recruiting | Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the NCT06633835 | Novavax | Phase 4 |
| Enrolling By Invitation | COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study NCT06478420 | University of Oxford | Phase 1 |
| Completed | Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated NCT06283459 | Imunon | Phase 1 / Phase 2 |
| Completed | Development and Validation of (Bio)Sensors for the Identification of Pathogens NCT06548841 | University of Bologna | — |
| Completed | A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults NCT06237049 | Pfizer | Phase 2 |
| Withdrawn | Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women NCT06997653 | Health Institutes of Turkey | Phase 2 |
| Enrolling By Invitation | Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection NCT06401720 | Karolinska Institutet | — |
| Recruiting | Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India NCT06168019 | Boston University | — |
| Completed | A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 NCT06147063 | AstraZeneca | Phase 1 |
| Completed | The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection NCT06065176 | Sarang K. Yoon, DO, MOH | Phase 4 |
| Completed | SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings NCT06191393 | Aptitude Medical Systems | N/A |
| Unknown | Eficacia Ventilatoria y Remolacha NCT06217211 | Hospital de Mataró | N/A |
| Unknown | Impact of Sleep Disorders on Innate Immunity in COVID-19 Patients NCT06341374 | Parc Taulí Hospital Universitari | — |
| Unknown | FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol NCT05928507 | Baebies, Inc. | — |
| Completed | Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects NCT06063330 | Red Queen Therapeutics, Inc. | Phase 1 |
| Completed | COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO) NCT06255860 | Association Clinique Thérapeutique Infantile du val de Marne | — |
| Completed | Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults NCT06026514 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Infl NCT05981846 | Hipra Scientific, S.L.U | Phase 2 |
| Unknown | To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M NCT05733780 | Bioxytran Inc. | Phase 2 |
| Completed | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals NCT05997290 | BioNTech SE | Phase 2 / Phase 3 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccine NCT05933512 | Sinocelltech Ltd. | Phase 2 |
| Unknown | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines NCT05952505 | Shanghai Municipal Center for Disease Control and Prevention | Phase 4 |
| Unknown | A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine NCT06113731 | CNBG-Virogin Biotech (Shanghai) Ltd. | Phase 2 |
| Withdrawn | Safety and Immunogenicity of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) as a Booster NCT05465902 | WestVac Biopharma Co., Ltd. | Phase 2 |
| Withdrawn | Lollipop COVID-19 Testing Study NCT05472077 | University of Wisconsin, Madison | N/A |
| Recruiting | COVID-19: Early Detection of Worsening by Voice and Respiratory Pattern Characteristics NCT05892549 | Direction Centrale du Service de Santé des Armées | — |
| Completed | Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection NCT05897541 | Shionogi | Phase 3 |
| Completed | Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of NCT06234956 | Hipra Scientific, S.L.U | Phase 2 |
| Completed | A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of C NCT05799495 | Pfizer | Phase 2 |
| Unknown | Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study . NCT05862480 | University of Monastir | N/A |
| Unknown | Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic P NCT05780450 | Fundación Universidad Católica de Valencia San Vicente Mártir | N/A |
| Unknown | A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine NCT06113744 | CNBG-Virogin Biotech (Shanghai) Ltd. | Phase 1 |
| Completed | Project STARFISH - PRJ0002679 NCT05727202 | Thermo Fisher Scientific, Inc | — |
| Withdrawn | Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendu NCT05085574 | Leidos Life Sciences | Phase 2 |
| Unknown | Booster Study of PTX-COVID19-B in Adults Aged 18 Years and Older NCT05534048 | Everest Medicines (Singapore) Pte. Ltd. | Phase 3 |
| Unknown | Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older NCT05534035 | Everest Medicines (Singapore) Pte. Ltd. | Phase 3 |
| Unknown | The ACDC Study Assessing Cognitive Deterioration in COVID-19 NCT05855434 | NHS Grampian | — |
| Unknown | Hyperbaric Oxygen Therapy Improves Brain Function in Patients With Cognitive Decline After COVID-19 Infection. NCT05715801 | The First Affiliated Hospital of Zhejiang Chinese Medical University | N/A |
| Active Not Recruiting | Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations NCT05667597 | Maria Goossens | N/A |
| Completed | Effect of an Online Self-help Psychological Intervention on Non-ICU Specialty Care During the COVID-19 Outbrea NCT05713305 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Recruiting | COVID-19 Transmission and Morbidity in Malawi NCT05973084 | Boston University | — |
| Completed | Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study NCT05794412 | University Hospital, Geneva | — |
| Completed | Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS) NCT05687877 | AstraZeneca | — |
| Completed | Consequences in ICU of Vaccination Status of Covid-19 Patients NCT06191341 | Centre Hospitalier Régional Metz-Thionville | — |
| Unknown | Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid NCT05633433 | Shanghai Henlius Biotech | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years NCT05308576 | Sinocelltech Ltd. | Phase 3 |
| Unknown | Differential Diagnosis of Persistent COVID-19 by Artificial Intelligence NCT05629793 | Fundacin Biomedica Galicia Sur | N/A |
| Active Not Recruiting | Mechanism and Immune Function Analysis of SARS-CoV-2 Infection in Hematologic Tumors NCT05683353 | Peking University First Hospital | — |
| Unknown | Randomised Clinical Trial to Evaluate the Efficacy of an Online Cognitive Rehabilitation Programme (COPERIA-CO NCT05629897 | Fundacin Biomedica Galicia Sur | N/A |
| Unknown | Efficacy of a Physical and Respiratory Rehabilitation Program for Patients With Persistent COVID-19 (SARS-CoV- NCT05629884 | Fundacin Biomedica Galicia Sur | N/A |
| Completed | Association Between Post-covid Infection Status and Perioperative Morbidity: A Ambispective Cohort Study NCT05689840 | Peking Union Medical College Hospital | — |
| Terminated | Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies NCT05315583 | Centre Hospitalier Régional d'Orléans | N/A |
| Withdrawn | Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Pa NCT05596045 | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
| Recruiting | SARS-CoV-2 Specific Antibody Responses and Impact for COVID-19 Disease in Ethiopia NCT06435403 | Michael Hoelscher | — |
| Completed | Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. NCT05710783 | Laboratorio Avi-Mex, S.A. de C.V. | Phase 2 / Phase 3 |
| Completed | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People NCT05541861 | BioNTech SE | Phase 1 |
| Unknown | SARS-CoV-2 in Stools Compared to Respiratory Viral Strains. NCT05567419 | Central Hospital, Nancy, France | — |
| Completed | An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are NCT05594147 | Bayer | — |
| Completed | A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Con NCT05765279 | Beijing Ditan Hospital | N/A |
| Unknown | The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled NCT05642910 | Southeast University, China | N/A |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Popul NCT05522829 | Sinocelltech Ltd. | Phase 2 |
| Completed | Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy NCT05523141 | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
| Withdrawn | COVID-19 Paediatric VLA2001-321 Study NCT05298644 | Valneva Austria GmbH | Phase 2 / Phase 3 |
| Completed | Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients NCT05523739 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Phase 1 |
| Completed | Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults NCT05383560 | Sheba Medical Center | Phase 2 |
| Completed | COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation NCT05555030 | New Day Diagnostics | N/A |
| Completed | A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 NCT05305547 | Shionogi | Phase 3 |
| Completed | A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a NCT06381843 | WestVac Biopharma Co., Ltd. | N/A |
| Unknown | Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19 NCT05516550 | PHARMENTERPRISES LLC | Phase 2 / Phase 3 |
| Completed | The Canadian Respiratory Research Network Long COVID-19 Study NCT05181670 | Sunnybrook Health Sciences Centre | — |
| Completed | A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals NCT05472038 | BioNTech SE | Phase 2 / Phase 3 |
| Terminated | EuGeni Rapid Antigen Test for the Qualitative Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SA NCT05618561 | AnteoTech Ltd | — |
| Completed | Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults NCT05463068 | Novavax | Phase 3 |
| Completed | Safety and Immunogenicity of Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster NCT05463354 | WestVac Biopharma Co., Ltd. | Phase 2 |
| Unknown | Evaluation of the Efficacy and Safety of Molnupiravir Treatment in Mild/Moderate Covid-19 Patients. NCT06223932 | Serap Yavuz | — |
| Completed | Booster Dose Study to Assess the Safety and Immunogenicity of ACM-001 Administered Intramuscularly or Intranas NCT05385991 | ACM Biolabs | Phase 1 |
| Completed | rSIFN-co Among Healthy Subjects and Subjects With Mild or Asymptomatic COVID-19 NCT05485584 | Sichuan Huiyang Life Science and Technology Corporation | Phase 2 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged NCT05329051 | Sinocelltech Ltd. | Phase 2 |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose NCT05345873 | Sinocelltech Ltd. | Phase 2 |
| Completed | Investigation of the Persistence of SARS-CoV-2 in the Olfactory Mucosa of Patients With Prolonged Symptoms of NCT05220241 | Fondation Ophtalmologique Adolphe de Rothschild | N/A |
| Unknown | A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More NCT05439824 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 2 |
| Completed | Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 P NCT05844202 | Alvea Holdings, LLC | Phase 1 |
| Completed | Effect of Local Treatment(Carrageenan Nasal Spray and PVP-I Mouthwash) in Reducing Viral Load in Patients With NCT05049213 | National Taiwan University Hospital | Phase 4 |
| Terminated | A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf NCT05367843 | Speransa Therapeutics | Phase 1 |
| Completed | A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19 NCT05747677 | Beijing Ditan Hospital | N/A |
| Withdrawn | Long Term Outcomes in COVID-19 Patients Recruited in the CORIST Project NCT04907890 | Neuromed IRCCS | — |
| Completed | Evaluate the Pharmacokinetics of BAT2022 in Healthy Chinese Subjects NCT05518695 | Bio-Thera Solutions | Phase 1 |
| Terminated | Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 NCT05438498 | MediMergent, LLC | Phase 3 |
| Unknown | Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine NCT05409261 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Unknown | Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults. NCT05490108 | Shanghai Zerun Biotechnology Co.,Ltd | Phase 1 / Phase 2 |
| Completed | Evaluation of the Relationship of Vitamin D and Vitamin D Binding Protein With Disease Severity in Pediatric S NCT05598957 | Marmara University | — |
| Completed | Impact of the COVID-19 Pandemic on the Health Status of People Aged 75 and Over and Their Caregivers NCT05249868 | Gerencia de Atención Primaria, Madrid | — |
| Recruiting | Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome NCT05421208 | Vanderbilt University Medical Center | N/A |
| Recruiting | Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19 NCT05384561 | Université du Québec à Trois-Rivières | N/A |
| Unknown | A Study to Evaluate the Immunogenicity and Safety of Two Recombinant Protein COVID-19 Vaccines in Population A NCT05323461 | Sinocelltech Ltd. | Phase 3 |
| Completed | Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines NCT05372588 | Novavax | Phase 3 |
| Completed | COVID-19 Observational Research Collaboratory NCT05394025 | VA Office of Research and Development | — |
| Completed | Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same NCT07408297 | Victoria Biomedical Research Institute | Phase 2 |
| Completed | Inhibition of Bradykinin in COVID-19 Infection With Icatibant NCT05407597 | Belfast Health and Social Care Trust | Phase 2 / Phase 3 |
| Completed | A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immun NCT05303402 | Hipra Scientific, S.L.U | Phase 2 / Phase 3 |
| Completed | VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infec NCT05364242 | Valneva Austria GmbH | Phase 2 / Phase 3 |
| Completed | Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Cli NCT05364268 | AudibleHealth AI, Inc. | — |
| Unknown | The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray NCT05552950 | Chemi-Pharm AS | Phase 4 |
| Completed | To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID NCT05351437 | Memo Therapeutics AG | Phase 1 |
| Unknown | Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea NCT05409300 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Completed | Efficacy and Safety of Nasal Spray Solution Containing Human IgG1 Anti-COVID-19 Antibody Cocktail NCT05358873 | Chulalongkorn University | N/A |
| Completed | Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age NCT05310084 | BioNTech SE | Phase 3 |
| Completed | Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients NCT05334654 | University Magna Graecia | N/A |
| Completed | Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19 NCT05256589 | Sona Nanotech Inc | N/A |
| Active Not Recruiting | Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos NCT05697068 | San Diego State University | N/A |
| Completed | Evaluation of Point-of-Care (EPOC) for COVID-19 NCT05227404 | University of Minnesota | — |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E in Population Aged NCT05239806 | Sinocelltech Ltd. | Phase 2 |
| Withdrawn | A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vac NCT05308602 | Sinocelltech Ltd. | Phase 2 |
| Completed | Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients NCT05338736 | University Magna Graecia | — |
| Completed | Tobacco Use and the Risk of COVID-19 and Adverse Outcomes NCT05321433 | Karolinska Institutet | — |
| Completed | A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19 NCT05263908 | Pfizer | — |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years an NCT05238454 | Sinocelltech Ltd. | Phase 2 |
| Unknown | A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Pr NCT05238441 | Sinocelltech Ltd. | Phase 2 |
| Unknown | Viral Load Analysis of the SARS-CoV-2 Virus in Nose Versus Mouth Sites NCT05769803 | IRCCS Sacro Cuore Don Calabria di Negrar | N/A |
| Completed | Impact of the Postponement of Surgery on Postoperative Morbidity After Sars-cov-2 Infection NCT05336110 | Société Française d'Anesthésie et de Réanimation | — |
| Unknown | COVID-19 Vaccination Status and The Clinical Outcomes of Long COVID-19 Patients NCT05587868 | Indonesia University | — |
| Recruiting | NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19 NCT05292274 | NYU Langone Health | — |
| Unknown | Prevalence of Knowledge, Attitudes and Perception of Covid Vaccine in Iraq. A Cross Sectional Study NCT05256602 | AlFayhaa General Hospital | — |
| Completed | Chronic Mouth Breathing and SARS-CoV-2 Positivity in the Pediatric Population NCT07063134 | Dokuz Eylul University | — |
| Active Not Recruiting | Understanding the Long-term Impact of COVID on Children and Families NCT05172011 | NYU Langone Health | — |
| Completed | A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS NCT05112848 | Novavax | Phase 2 |
| Unknown | Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique NCT05362682 | International Vaccine Institute | — |
| Unknown | This Trial is a Clinical Performance Validation Study That Will Evaluate the Clinical Agreement of the Sky Med NCT05491993 | Sky Medical Supplies & Equipments, LLC | N/A |
| Completed | Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Heal NCT05230940 | Health Institutes of Turkey | Phase 2 |
| Unknown | Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults NCT05216484 | Chinese Academy of Medical Sciences | Phase 3 |
| Completed | Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach NCT05557539 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | N/A |
| Completed | A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Ind NCT05210101 | Sophia Koo, M.D. | Phase 2 |
| Completed | A Study of EDP-235 in Healthy Subjects NCT05246878 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Withdrawn | AIDI - Research & Development of a Multisensor-Based Machine Learning Technology for Real-Time Automated Detec NCT05220306 | AIDAR Health, Inc. | N/A |
| Completed | I VACCIN Hospitalization of COVID-19 Patients NCT05244343 | Eshmoun Clinical Research Center | — |
| Completed | Phase 2b Booster Vaccination (TURKOVAC) Against COVID-19 NCT05210179 | Health Institutes of Turkey | Phase 2 |
| Completed | Efficacy of Oral Rinses for Inactivation of COVID-19 (MOR2) NCT05178173 | University of North Carolina, Chapel Hill | N/A |
| Terminated | Efficacy of ADW S-100 Ionized Water Nasal Spray in Decreasing SARS-Cov-2 Viral Load. NCT05290987 | P & B Group | N/A |
| Completed | Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC NCT05514691 | bioLytical Laboratories | N/A |
| Completed | A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2 NCT05113862 | Gylden Pharma Ltd | Phase 1 |
| Completed | Nosocomial COVID-19 Infections in Patients Hospitalized at the Metz-Thionville Regional Hospital in 2021 NCT05567874 | Centre Hospitalier Régional Metz-Thionville | — |
| Completed | Physical and Cognitive Impairments in People Suffering From Long COVID NCT05216536 | Laval University | — |
| Unknown | Impact of Genetic Polymorphisms of Vasoactive Peptides on the Prognosis of Patients With COVID19 NCT05160779 | Leonardo Paroche de Matos | N/A |
| Unknown | Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness NCT05172063 | Children's Cancer Hospital Egypt 57357 | — |
| Completed | LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) NCT05077332 | Leidos Life Sciences | Phase 2 |
| Unknown | An Educational Self-tracking Tool for Identification of SARS-CoV-2 Risk Transmission NCT05171829 | Hospital Clinic of Barcelona | N/A |
| Unknown | The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With mRNA NCT05043311 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Unknown | The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inact NCT05043285 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Unknown | Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine NCT05109559 | Mahidol University | Phase 1 / Phase 2 |
| Unknown | Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on NCT05163652 | Chinese Academy of Medical Sciences | Phase 3 |
| Withdrawn | ImmuneSense™ COVID-19 Cross-Reactivity Study NCT05112874 | Adaptive Biotechnologies | — |
| Completed | Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2) NCT05244330 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | CovidSurg-3: Outcomes of Surgery in COVID-19 Infection NCT05161299 | University of Birmingham | — |
| Completed | Effect of Sars-cov-2 on Donor Oocyte Quality and Quantity, a Multicenter Retrospective Study. NCT05562479 | Novafem | — |
| Completed | A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV- NCT05142306 | Emergent BioSolutions | Phase 1 |
| Terminated | SP16 as a Therapeutic for COVID-19 Induced ARDS NCT05135624 | Serpin Pharma, LLC | Phase 1 |
| Terminated | Transplacental Transmission of COVID-19 NCT05124574 | Centre Hospitalier Universitaire de Saint Etienne | — |
| Completed | Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern NCT05168813 | COVID-19 Prevention Network | Phase 2 / Phase 3 |
| Completed | Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pand NCT05394051 | Northwestern University | N/A |
| Withdrawn | Recovering From COVID-19 NCT05302960 | Imperial College London | — |
| Completed | Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence NCT05205746 | Laboratorio Avi-Mex, S.A. de C.V. | Phase 2 |
| Terminated | Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Inf NCT05109611 | Sanotize Research and Development corp. | Phase 3 |
| Unknown | A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW) NCT05036941 | Ascend Performance Materials | N/A |
| Completed | PERC Health Canada COVID-19 NCT05040763 | University of Calgary | N/A |
| Unknown | Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study. NCT05148845 | Wits Health Consortium (Pty) Ltd | Phase 3 |
| Completed | Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild CO NCT05599919 | Sanotize Research and Development corp. | Phase 3 |
| Completed | Mortality of Cancer Surgery During SARS CoV2 Pandemic NCT05240378 | Banaras Hindu University | — |
| Unknown | Immune Response to Third Dose of SARS-CoV-2 Vaccine in a Cohort of Cancer Patients on Active Treatment NCT05119738 | Pontificia Universidad Catolica de Chile | — |
| Recruiting | T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients NCT05141058 | Children's National Research Institute | Phase 1 |
| Completed | To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects NCT05017168 | Celltrion | Phase 1 |
| Completed | Safe and Healthy Schools NCT05105789 | University of Wisconsin, Madison | N/A |
| Unknown | A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol NCT05007275 | Imperial College London | Phase 1 |
| Completed | Phase 3 Booster Vaccination Against COVID-19 NCT05077176 | Health Institutes of Turkey | Phase 3 |
| Completed | COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability NCT05584189 | MP Biomedicals, LLC | N/A |
| Completed | Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant NCT05124509 | Pontificia Universidad Catolica de Chile | — |
| Terminated | Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19） NCT05065619 | Medicago | Phase 1 / Phase 2 |
| Withdrawn | COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, NCT04848467 | Bayer | Phase 3 |
| Unknown | Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID NCT05012826 | Centro Universitário Augusto Motta | N/A |
| Completed | Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild NCT05007236 | Rhizen Pharmaceuticals SA | Phase 2 |
| Suspended | Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia NCT04738136 | SolAeroMed Inc. | Phase 2 |
| Completed | COVID-19: SARS-CoV-2-CZ-PREVAL-II Study NCT05096962 | Institute of Health Information and Statistics of the Czech Republic | — |
| Completed | A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults NCT05037097 | Arcturus Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis NCT05520944 | Dr. Ferrer BioPharma | — |
| Completed | Diagnosis of Respiratory Viruses in Children With Rhinoswab Junior NCT05043623 | Murdoch Childrens Research Institute | N/A |
| Completed | COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the Unite NCT05020145 | Pfizer | — |
| Completed | Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants NCT05004181 | BioNTech SE | Phase 2 |
| Completed | Prospective COVID-19 Cohort Study, Dominican Republic NCT04898738 | Brigham and Women's Hospital | N/A |
| Unknown | The UK Interstitial Lung Disease Long-COVID19 Study (UKILD-Long COVID): Understanding the Burden of Interstiti NCT05514522 | Imperial College London | — |
| Completed | Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healt NCT05007509 | Laboratorios Hipra, S.A. | Phase 1 / Phase 2 |
| Active Not Recruiting | Post Acute Sequelae of COVID-19 NCT04964115 | Vanderbilt University Medical Center | — |
| Unknown | Low-field Magnetic Resonance Imaging of Pediatric COVID-19 NCT04990531 | University of Erlangen-Nürnberg Medical School | N/A |
| Active Not Recruiting | ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases NCT05467917 | Columbia University | — |
| Completed | Physiological Response to Prone Position in COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) NCT05092737 | University of Lausanne Hospitals | — |
| Completed | Evaluation of the Prevalence and Clinical Manifestation of SARS-CoV-2 Infection in a Population of Adult and P NCT06784687 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Unknown | PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACC NCT05279365 | DHR Health Institute for Research and Development | Phase 2 / Phase 3 |
| Completed | Evaluation of Post-vaccination Anti-SARS-CoV-2 Serological Response in Health Care Workers With a History of C NCT04934215 | Fondation Hôpital Saint-Joseph | — |
| Terminated | Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 NCT04778059 | US Biotest, Inc. | Phase 2 |
| Terminated | Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection NCT04834908 | Bharat Serums and Vaccines Limited | Phase 1 / Phase 2 |
| Completed | A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162 NCT04949490 | BioNTech SE | Phase 2 |
| Completed | Deciphering a Specific Signature of the Immunosenescence Induced in COVID-19+ Patients Versus Rheumatoid Arthr NCT04880720 | University Hospital, Montpellier | — |
| Completed | Safety and Efficacy of COVID-19 Prime-boost Vaccine in Bahrain NCT04993560 | Royal College of Surgeons in Ireland - Medical University of Bahrain | — |
| Unknown | Incidence of MIS-C and Other Complications Following SARS-CoV-2 Infection NCT05186597 | Rigshospitalet, Denmark | — |
| Completed | Novel Experimental COVID-19 Therapies Affecting Host Response NCT04924660 | Sean Collins | Phase 2 / Phase 3 |
| Completed | Booster Vaccination Against COVID-19 NCT04979949 | Health Institutes of Turkey | Phase 2 |
| Completed | Validation of 'Corona-T-test' for Assessment of SARS-COV-2-specific T-cell Response After COVID-19 or Vaccinat NCT05165719 | National Research Center for Hematology, Russia | — |
| Completed | A Phase IV Vaccine Study Under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2 (COVID-19) NCT06360744 | Jens D Lundgren, MD | Phase 4 |
| Recruiting | CU-COMMITS: COVID-19 Care in Black and Latino Communities and Households. Clinical and Molecular Outcomes of S NCT05467930 | Columbia University | — |
| Completed | The Potential Role of sRAGE, KL-6, and SP-D as Prognostic Factors in Children With COVID-19 NCT05619640 | Haseki Training and Research Hospital | — |
| Completed | To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVI NCT04955626 | BioNTech SE | Phase 3 |
| Completed | A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 NCT04940182 | RSV Therapeutics LLC | Phase 3 |
| Completed | Clinical Impact of COVID-19 by P.1 SARS-CoV-2 Lineage NCT04928469 | Hospital de Clinicas de Porto Alegre | — |
| Unknown | Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol NCT05384899 | University of Washington | — |
| Completed | Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection NCT04818216 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19 NCT04922788 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Phase 3 |
| Terminated | A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2 NCT04721535 | Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| Completed | Impact of PCSK9 Inhibition on Clinical Outcome in Patients During the Inflammatory Stage of the COVID-19 NCT04941105 | Collegium Medicum w Bydgoszczy | Phase 3 |
| Completed | Monitoring COVID-19 Vaccination Response in Fragile Populations NCT05222139 | University of Bologna | — |
| Completed | Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2 NCT04887948 | Pfizer | Phase 3 |
| Completed | Study of a Live rNDV Based Vaccine Against COVID-19 NCT04871737 | Laboratorio Avi-Mex, S.A. de C.V. | Phase 1 |
| Unknown | The Ontario Multi-Regional Hospital COVID-19 Registry (COREG)- Recovery Trajectory Sub-study NCT04868864 | Hamilton Health Sciences Corporation | — |
| Completed | Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes NCT05778383 | Parc de Salut Mar | Phase 4 |
| Terminated | Performance Study of SONA Saliva C-19 Rapid Test NCT04877002 | Sona Nanotech Inc | N/A |
| Completed | Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19 NCT06318208 | University of Rostock | — |
| Completed | PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 NCT04784767 | U.S. Army Medical Research and Development Command | Phase 1 |
| Unknown | Glycophosphopeptical AM3 A Potential Adjuvant in the Treatment of SARS-CoV-2 NCT04987554 | University of Valladolid | N/A |
| Unknown | Halodine Nasal Antiseptic in Patients With COVID-19 NCT04517188 | Halodine LLC | Phase 4 |
| Completed | A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID- NCT04816669 | BioNTech SE | Phase 3 |
| Terminated | Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19 NCT04748783 | University of North Carolina, Chapel Hill | Phase 2 |
| Completed | The LAVA (Lateral Flow Antigen Validation and Applicability) 2 Study for COVID-19 NCT05614427 | Alder Hey Children's NHS Foundation Trust | N/A |
| Completed | A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vacc NCT04811664 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | Smell in Covid-19 and Efficacy of Nasal Theophylline NCT04789499 | Washington University School of Medicine | Phase 2 |
| Completed | Safety and Tolerability of COVID-19 Vaccine (ABNCoV2) NCT04839146 | Radboud University Medical Center | Phase 1 |
| Completed | STREngthening COronavirus Disease 2019 (COVID-19) Surveillance in Africa NCT06170320 | Institut de Recherche pour le Developpement | — |
| Completed | Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 NCT04757818 | Dentaid SL | N/A |
| Completed | To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Wome NCT04754594 | BioNTech SE | Phase 2 / Phase 3 |
| Completed | A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose NCT04713553 | BioNTech SE | Phase 3 |
| Unknown | Breath Analysis of Patients Diagnosed With COVID-19 Using Infrared Spectroscopy NCT04867213 | McMaster University | — |
| Completed | Police COVID-19 Serosurvey NCT04643444 | University of Bern | — |
| Completed | Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load NCT04820803 | Rosa Tarrago | N/A |
| Completed | SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19) NCT04738695 | Sciensano | — |
| Unknown | Transmission of Respiratory Viruses in Households in The Gambia: a Longitudinal Cohort Study (TransVIR) NCT05952336 | Medical Research Council Unit, The Gambia | — |
| Completed | Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. NCT05172050 | Dompé Farmaceutici S.p.A | Phase 2 / Phase 3 |
| Unknown | Respiratory Aerosols in Patients With COVID-19 and Healthy Controls NCT04739020 | Johann Wolfgang Goethe University Hospital | N/A |
| Completed | Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission NCT04647305 | University of Los Andes, Columbia | N/A |
| Unknown | Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff NCT04799808 | Technische Universität Dresden | — |
| Unknown | Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection NCT04728919 | Tampere University Hospital | — |
| Unknown | COVID-19 VACCINE SAFETY AND EFFECTIVENESS NCT05133609 | Federal University of Espirito Santo | Phase 1 / Phase 2 |
| Active Not Recruiting | SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological P NCT05046470 | Université Catholique de Louvain | — |
| Unknown | Safety and Immunogenicity of an Inactivated Vaccine Against COVID-19 in Medical Workers NCT04795414 | Ruijin Hospital | — |
| Completed | Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell NCT04710394 | Washington University School of Medicine | N/A |
| Completed | Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals NCT04681430 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Completed | Cognitive, Emotional and Behavioural Impairments in Patients After Sars-Cov2 Infection NCT05143320 | Ospedale Generale Di Zona Moriggia-Pelascini | — |
| Completed | Security Efficacy COVID-19 Vaccination NCT05743361 | Istituto Auxologico Italiano | — |
| Completed | COVID-19: Infectious Potential of SARS-CoV-2 Intestinal Shedding in Pediatric Patients (INPOSIS) NCT05055466 | St. Anna Kinderkrebsforschung | — |
| Completed | Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly NCT04756466 | Biosearch S.A. | N/A |
| Unknown | Fenofibrate for Patients With COVID-19 Requiring Hospitalization NCT04661930 | Yaakov Nahmias | Phase 3 |
| Completed | Rutgers Pilot for PREDICT- Patient POC Test NCT05612724 | Rutgers, The State University of New Jersey | N/A |
| Unknown | Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Thera NCT04715360 | Hayandra Peduli Foundation | Phase 1 / Phase 2 |
| Terminated | Mouth Rinses for Inactivation of COVID-19 NCT04584684 | University of North Carolina, Chapel Hill | Phase 2 |
| Terminated | SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation NCT04631705 | University of Cologne | Phase 1 / Phase 2 |
| Completed | SCREENING AND SEROEPIDEMIOLOGY OF SARS-CoV-2 INFECTION AT THE UNIVERSITY OF BARCELONA: A CROSS-SECTIONAL STUDY NCT04784403 | Dr. Francisco Ciruela Alférez | — |
| Completed | Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study) NCT05074719 | University of Washington | — |
| Completed | SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion NCT04631666 | University of Cologne | Phase 1 / Phase 2 |
| Unknown | Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts NCT04788407 | Fundación Huésped | Phase 4 |
| Completed | Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19 NCT04868903 | University of Chicago | N/A |
| Completed | Subacute Thyroiditis in the SARS-CoV-2 Era NCT06391515 | University of Modena and Reggio Emilia | — |
| Active Not Recruiting | Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults NCT04636697 | Medicago | Phase 2 / Phase 3 |
| Recruiting | Exercise in Child Health NCT05359991 | University of California, Irvine | N/A |
| Completed | Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients NCT04621123 | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | Phase 2 |
| Terminated | A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and t NCT04582318 | NGM Biopharmaceuticals, Inc | Phase 1 / Phase 2 |
| Unknown | Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Out NCT04595136 | United Medical Specialties | Phase 1 / Phase 2 |
| Completed | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in NCT04588480 | BioNTech SE | Phase 4 |
| Completed | Evaluation of a Screening Program for SARS-CoV-2 Infection in the General Population Based on the Use of New D NCT04578509 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Benefit of Expanded Surveillance of Nursing Homes During the COVID-19 Pandemic NCT04933981 | University of Cologne | — |
| Unknown | WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients NCT04643548 | University Hospital, Clermont-Ferrand | — |
| Completed | Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test NCT04609969 | Centre Hospitalier Régional d'Orléans | N/A |
| Unknown | REMdesivir-HU Clinical Study and Severe Covid-19 Patients NCT04610541 | University of Pecs | Phase 3 |
| Completed | ImmuneSense™ COVID-19 Study NCT04583982 | Adaptive Biotechnologies | — |
| Completed | Clinical Trial of Favipiravir Treatment of Patients With COVID-19 NCT04600999 | University of Pecs | Phase 3 |
| Terminated | Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2 NCT04815018 | Pathnostics | — |
| Completed | A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 I NCT04602000 | Celltrion | Phase 2 / Phase 3 |
| Unknown | COVID-10 in the Pediatric Population: SARS-CoV-2 Seropositivity NCT04690114 | Shaare Zedek Medical Center | — |